-
公开(公告)号:EP3966239A1
公开(公告)日:2022-03-16
申请号:EP20723153.1
申请日:2020-05-08
-
2.
公开(公告)号:EP4244229A1
公开(公告)日:2023-09-20
申请号:EP21806745.2
申请日:2021-11-12
发明人: ECKHARDT, Matthias , WILLWACHER, Marina, Kristina , PRESTLE, Juergen , KONTES, Ferenc , THOMAS, Leo , TAUTERMANN, Christofer, Siegfried , WIEDENMAYER, Dieter
IPC分类号: C07D495/14 , A61P27/02 , A61K31/495
-
公开(公告)号:EP4034161A1
公开(公告)日:2022-08-03
申请号:EP20781286.8
申请日:2020-09-24
发明人: ZIPPEL, Nina , GUPTA, Pankaj , HAN, Fei , HUANG, Yining , LOW, Sarah , PRESTLE, Juergen , THOMAS, Leo
IPC分类号: A61K39/395 , A61P27/00 , C07K16/28
-
4.6,7,8,9-TETRAHYDRO-5H-1,4,7,10A-TETRAAZA-CYCLOHEPT[F]INDENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR PREPARING THEM 有权
标题翻译: -6,7,8,9- TETRA HYDRO-5H-1,4,7,10A- TETRAAZACYCLOHEPT [f]茚衍生物,其药物组合物含有这些化合物,它们的用途和PROCESS FOR THEIR公开(公告)号:EP2384328B1
公开(公告)日:2013-02-13
申请号:EP09756757.2
申请日:2009-11-26
发明人: MUELLER, Stephan-Georg , BROWN, Christoper, John , HEIFETZ, Alexander , NOSSE, Bernd , PRESTLE, Juergen , PREVOST, Natacha , RUDOLF, Klaus , SCHEUERER, Stefan , SCHINDLER, Marcus , STENKAMP, Dirk , THOMAS, Leo , TYE, Heather
IPC分类号: C07D487/14 , A61K31/519 , A61P25/00 , A61P3/00
CPC分类号: C07D487/14
-
5.6,7,8,9-TETRAHYDRO-5H-1,4,7,10A-TETRAAZA-CYCLOHEPT[F]INDENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR PREPARING THEM 有权
标题翻译: -6,7,8,9- TETRA HYDRO-5H-1,4,7,10A- TETRAAZACYCLOHEPT [f]茚衍生物,其药物组合物含有这些化合物,它们的用途和PROCESS FOR THEIR公开(公告)号:EP2384328A1
公开(公告)日:2011-11-09
申请号:EP09756757.2
申请日:2009-11-26
发明人: MUELLER, Stephan-Georg , BROWN, Christoper, John , HEIFETZ, Alexander , NOSSE, Bernd , PRESTLE, Juergen , PREVOST, Natacha , RUDOLF, Klaus , SCHEUERER, Stefan , SCHINDLER, Marcus , STENKAMP, Dirk , THOMAS, Leo , TYE, Heather
IPC分类号: C07D487/14 , A61K31/519 , A61P25/00 , A61P3/00
CPC分类号: C07D487/14
摘要: The present invention relates to compounds defined by formula (I), wherein the groups X, Y, W and R
1 to R
4 are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are agonists of the 5-HT2C receptor, and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this receptor, such as metabolic and CNS-related disorders.
-
-
-
-